4521 — Kaken Pharmaceutical Co Balance Sheet
0.000.00%
- ¥152bn
- ¥76bn
- ¥72bn
- 95
- 83
- 94
- 100
Annual balance sheet for Kaken Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 73,321 | 77,305 | 74,624 | 74,260 | 65,324 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 21,800 | 20,549 | 20,260 | 19,268 | 23,744 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 108,336 | 113,662 | 110,613 | 109,903 | 106,974 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 25,518 | 25,020 | 25,734 | 25,498 | 25,355 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 157,875 | 163,332 | 165,181 | 166,328 | 171,623 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 21,655 | 21,276 | 19,049 | 20,838 | 19,024 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 29,407 | 27,075 | 27,434 | 30,070 | 27,868 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 128,468 | 136,257 | 137,747 | 136,258 | 143,755 |
Total Liabilities & Shareholders' Equity | 157,875 | 163,332 | 165,181 | 166,328 | 171,623 |
Total Common Shares Outstanding |